{"id":391417,"date":"2015-04-23T00:00:00","date_gmt":"2015-04-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0315-biopharma-crohns-disease-moderate-to-severe-decision-base-us-2015\/"},"modified":"2026-04-17T23:44:03","modified_gmt":"2026-04-17T23:44:03","slug":"dbasim0315-biopharma-crohns-disease-moderate-to-severe-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0315-biopharma-crohns-disease-moderate-to-severe-decision-base-us-2015\/","title":{"rendered":"Crohn\u2019s Disease (Moderate to Severe) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>Are new drug classes expected to address the considerable unmet need?<\/em><\/p>\n<p>Crohn\u2019s disease (CD) is a chronic gastrointestinal inflammatory disorder affecting over 1 million people in the major markets in our study, with a sizable market opportunity. TNF-\u03b1 inhibitors infliximab (Janssen\/Merck\/Mitsubishi Tanabe\u2019s Remicade) and adalimumab (AbbVie\/Eisai\u2019s Humira) dominate the biologics market space; however, this market will be increasingly competitive, starting with the recent launch of a new agent, vedolizumab (Takeda\u2019s Entyvio). Significant opportunity exists for emerging therapies to differentiate themselves by addressing important unmet needs such as increased benefit to induction of remission and maintenance of clinical remission (without corticosteroids), achieving mucosal healing, and\/or providing a more-convenient delivery formulation (i.e., oral). Several compounds in new drug classes currently in clinical development show promise in some of these areas but will also need to demonstrate safety profiles comparable to or better than TNF-\u03b1 inhibitors to experience significant uptake.<\/p>\n","protected":false},"template":"","class_list":["post-391417","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391417\/revisions"}],"predecessor-version":[{"id":394540,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391417\/revisions\/394540"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}